Avidity Biosciences Inc
Research Avidity Biosciences Inc (RNA) on Bullrun: market cap USD 239.48M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRNA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 239.48M
- Financial periodQ1 2026
- RevenueUSD 19.64M
- Net income-USD 16.63M
- Free cash flow-USD 33.24M
Valuation Snapshot
latest market cap is USD 239.48M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 18.75M | -USD 495.60M | -USD 511.78M | n/a | -7.86 | USD 270.00M | USD 3.67M | USD 207.29M |
| FY2024 | USD 10.90M | -USD 266.24M | -USD 212.63M | n/a | -2.89 | USD 219.87M | USD 6.80M | -USD 61.11M |
| FY2023 | n/a | n/a | -USD 123.29M | n/a | n/a | USD 185.08M | USD 9.85M | USD 500.76M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 239.48M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 10.87B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.49B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 716.55M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.51B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.14B | n/a | n/a | n/a |
About Avidity Biosciences Inc
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Avidity Biosciences Inc's market cap?
Avidity Biosciences Inc's market capitalization is USD 239.48M.
What does Avidity Biosciences Inc do?
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases.